FDA approves marketing of first device to treat ADHD

FDA approves marketing of first device to treat ADHD

(HealthDay)—Marketing has been approved for the first medical device to treat attention-deficit/hyperactivity disorder (ADHD), the U.S. Food and Drug Administration announced Friday.

The Monarch external Trigeminal Nerve Stimulation (eTNS) System is available by prescription only for aged 7 to 12 years old who are not currently taking prescription medication for ADHD. The FDA indicates that the Monarch eTNS System should be used in the home under caregiver supervision. The , which is about the size of a cell phone, according to the FDA, generates a low-level electrical pulse to the trigeminal nerve from a wire to a small patch placed above the patient's eyebrows. The patient should feel a tingling sensation.

Clinical trials have shown it may take up to four weeks to see results, and patients should consult with caregivers after four weeks to assess the treatment's effectiveness. In a clinical trial of 62 patients with moderate-to-severe ADHD, those who used the Monarch eTNS System nightly for four weeks had a statistically significant improvement in their ADHD symptoms compared with those who received placebo. Their average ADHD Rating Scale score decreased from 34.1 to 23.4 points compared with a decrease from 33.7 to 27.5 points for those who received placebo.

Commonly reported side effects with the Monarch eTNS System include drowsiness, increased appetite, trouble sleeping, teeth clenching, headache, and fatigue. The device is contraindicated in children younger than 7, patients with active implantable pacemakers or neurostimulators, and patients with body-worn devices like insulin pumps.

Marketing authorization was granted to NeuroSigma.


Explore further

Trigeminal nerve stimulation beats sham tx for peds ADHD

More information: More Information

Copyright © 2019 HealthDay. All rights reserved.

Citation: FDA approves marketing of first device to treat ADHD (2019, April 22) retrieved 16 October 2019 from https://medicalxpress.com/news/2019-04-fda-device-adhd.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
7 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more